Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» remestemcel-L
remestemcel-L
Mesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19
Mesoblast shares plunge 32% after stem-cell therapy not likely to meet target for reducing mortality due to COVID-19
Seeking Alpha
Mesoblast
clinical trials
remestemcel-L
COVID-19
Flag link:
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
BioSpace
Novartis
Mesoblast
remestemcel-L
COVID-19
ARDS
clinical trials
Flag link:
Mesoblast hit by FDA rejection, request to run another trial
Mesoblast hit by FDA rejection, request to run another trial
Fierce Biotech
Mesoblast
cell therapy
clinical trials
remestemcel-L
graft vs host disease
FDA
Flag link:
Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon
Clinical Trials Of Mesoblast’s Stem Cell Treatment For COVID-19 Set To Begin Soon
Forbes
Mesoblast
Australia
clinical gtrials
ARDS
COVID-19
stem cells
remestemcel-L
Flag link:
Mesoblast poised to file cell therapy for GVHD in US
Mesoblast poised to file cell therapy for GVHD in US
Pharmaforum
Mesoblast
stem cells
graft vs host disease
FDA
remestemcel-L
Flag link:
